Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Naltrexone Implants for Opioid Relapse Prevention
NCT00269607Phase 3Terminated
- Sponsor
- University of Oslo
- Start
- May 2005
- Primary completion
- Dec 2006
- Modality
- Small Molecules
01
Overview
Phase 3, open-label trial of naltrexone in opioid use disorder (OUD) (2 arms), sponsored by University of Oslo. Primary endpoints: Drug use by self report and hair analysis at 18 months, Days in work or education at 18 months and 1 more. Started May 2005; status: terminated.
02
Drugs
naltrexone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT00269607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00269607.